Bambusa Therapeutics Reports Positive Phase 1 BBT002 Data at EAACI 2026
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary results from the multiple ascending dose (MAD) cohorts of...
Eosinophils
Advertisement
Advertisement
